UCB, a prominent global biopharmaceutical company, is set to make a significant investment in Georgia by establishing its first U.S. pharmaceutical biologics manufacturing facility. This ambitious project, with a budget of $2 billion, aims to create 330 jobs over the upcoming years and will be located within the Rowen Foundation’s innovative science and learning campus in Gwinnett County.
Commitment to Innovation and Growth
Headquartered in Smyrna, Georgia, UCB has long been committed to advancing healthcare solutions in the fields of neurology and immunology. The CEO of UCB, Jean-Christophe Tellier, emphasized the company’s confidence in its long-term growth potential within the United States. This investment reflects UCB’s dedication to enhancing its biologics manufacturing capabilities, thereby supporting its innovation pipeline and generating high-quality employment opportunities in a state renowned for its skilled workforce and robust manufacturing history.
Economic Impact and Community Benefits
The establishment of this facility is expected to yield a total economic impact of approximately $5 billion, illustrating the broader benefits it will deliver to the local community. Governor Brian Kemp highlighted the importance of this investment as a pivotal milestone for Georgia’s life sciences sector, which reinforces the state’s role as a dynamic hub for innovation.
A State-of-the-Art Manufacturing Campus
UCB’s new facility will serve as an anchor tenant for the expansive 2,000-acre Rowen community, which is designed to promote collaboration and knowledge sharing among various stakeholders. The campus is poised to leverage cutting-edge technologies, including artificial intelligence, robotics, and automation, while also focusing on sustainable practices that optimize resource use. This digital-first approach positions UCB at the forefront of biologics manufacturing.
Collaboration with State and Local Entities
The Georgia Department of Economic Development, in collaboration with various local organizations, played an instrumental role in supporting UCB’s decision to invest in Gwinnett County. This teamwork underscores the strength of Georgia’s life sciences ecosystem, which connects innovative companies with top-tier partners in research, education, and infrastructure.
Regional Advantages and Workforce Potential
Gwinnett County’s commitment to fostering a collaborative environment for discovery and innovation aligns perfectly with UCB’s vision. Chairwoman Nicole Love Hendrickson expressed enthusiasm regarding the investment, emphasizing Gwinnett’s diverse and highly skilled talent pool. As one of the most vibrant counties in the nation, Gwinnett is strategically positioned to support UCB’s growth and ongoing success.
Future of Biologics in Georgia
The decision to locate its new manufacturing facility in Gwinnett County reflects UCB’s recognition of the region’s strengths in the life sciences sector. Katie Kirkpatrick, President and CEO of the Metro Atlanta Chamber, noted that UCB’s investment not only signifies the region’s current capabilities but also its potential to drive future breakthroughs in the industry.
Conclusion: A Vision for Tomorrow
UCB’s $2 billion investment in Georgia represents more than just a new manufacturing facility; it signifies a commitment to innovation, economic growth, and community development. As the biopharmaceutical landscape continues to evolve, UCB’s strategic move enhances Georgia’s position as a premier hub for biologics manufacturing, paving the way for future advancements in healthcare.
- Key Takeaways:
- UCB’s new facility will create 330 jobs and promote economic growth.
- The project emphasizes sustainable manufacturing practices.
- Collaboration between state and local organizations was crucial for this investment.
- Gwinnett County offers a skilled workforce and a vibrant business environment.
- UCB’s investment underscores Georgia’s role as a leader in life sciences innovation.
Read more → businessfacilities.com